Literature DB >> 8862372

Transabdominal esophagogastric devascularization as treatment for variceal hemorrhage.

G Jin1, L F Rikkers.   

Abstract

BACKGROUND: During the past 18 years we have used a selective operative approach for variceal bleeders in whom endoscopic sclerotherapy failed or sclerotherapy was not indicated. Esophagogastric devascularization with splenectomy has been reserved for unshuntable patients and for those in whom a shunt was deemed inadvisable. The purposes of this study are to describe the surgical procedure technique and indications for esophagogastric devascularization and to report its long-term results.
METHODS: Thirty-two patients who underwent either a limited (n = 9) or extensive (n = 23) esophagogastric devascularization procedure without esophageal transection for variceal bleeding were retrospectively reviewed. Common indications were thrombosis of all splanchnic veins (n = 12), distal splenorenal shunt thrombosis (n = 7), generalized portal hypertension with isolated splenic vein thrombosis (n = 5), and symptomatic splenomegaly or severe hypersplenism (n = 6). Eighteen patients (56%) had cirrhosis, eleven (34%) received an emergency operation, and eighteen (56%) bled from gastric varices.
RESULTS: Three patients with Child's class C disease undergoing emergency surgery died during the early postoperative interval. Rebleeding occurred in nine surviving patients (31%) and was the cause of death in three. Rebleeding rates for the limited and extensive devascularization procedures were 50% and 24%, respectively. Only one of 11 patients with diffuse splanchnic venous thrombosis without liver disease has died. The 5-year survival rate of patients with liver disease was 51%. Only two patients experienced postoperative encephalopathy.
CONCLUSIONS: When used in selected patients, esophagogastric devascularization without esophageal transection is a reasonably effective alternative to shunt surgery.

Entities:  

Mesh:

Year:  1996        PMID: 8862372     DOI: 10.1016/s0039-6060(96)80011-0

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  8 in total

1.  What are the essential components of a transabdominal devascularization procedure for bleeding esophageal varices?

Authors:  Dinesh Singhal; Neerav Goyal; A S Soin; Subash Gupta; S Nundy
Journal:  World J Surg       Date:  2007-04       Impact factor: 3.352

Review 2.  Current management of portal hypertension.

Authors:  Andrew S Wright; Layton F Rikkers
Journal:  J Gastrointest Surg       Date:  2005 Sep-Oct       Impact factor: 3.452

3.  Surgical portosystemic shunts versus devascularisation procedures for prevention of variceal rebleeding in people with hepatosplenic schistosomiasis.

Authors:  Chikwendu J Ede; Dimitrinka Nikolova; Martin Brand
Journal:  Cochrane Database Syst Rev       Date:  2018-08-03

4.  The changing spectrum of treatment for variceal bleeding.

Authors:  L F Rikkers
Journal:  Ann Surg       Date:  1998-10       Impact factor: 12.969

Review 5.  Splenic vein thrombosis and gastrointestinal bleeding in chronic pancreatitis.

Authors:  Sharon M Weber; Layton F Rikkers
Journal:  World J Surg       Date:  2003-10-13       Impact factor: 3.352

6.  Long-term results of fundectomy and periesophagogastric devascularization in patients with gastric fundal variceal bleeding.

Authors:  Joo-Ho Lee; Ho-Seong Han; Hyun-Ah Kim; Min-Young Koo
Journal:  World J Surg       Date:  2009-10       Impact factor: 3.352

7.  Foam Sclerotherapy during Shunt Surgery for Portal Hypertension and Varices.

Authors:  Zhe Zhang; Xueming Chen; Chenyu Li; Hai Feng; Hongzhi Yu; Renming Zhu; Tianyou Wang
Journal:  Open Med (Wars)       Date:  2017-11-22

8.  Long-term results with the modified Sugiura procedure for the management of variceal bleeding: standing the test of time in the treatment of bleeding esophageal varices.

Authors:  D Voros; A Polydorou; G Polymeneas; I Vassiliou; A Melemeni; K Chondrogiannis; V Arapoglou; G P Fragulidis
Journal:  World J Surg       Date:  2012-03       Impact factor: 3.352

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.